Sep 29 2009
Hythiam, Inc. (NASDAQ:HYTM) announced today that the results of a double-blind, placebo-controlled study on the impact of the medical component of the PROMETA® Treatment Program on alcohol dependent subjects was accepted and published in the Journal of Clinical Psychopharmacology, a leading scholarly publication in psychopharmacology that features articles reporting on clinical trials and studies. The article is titled, “Efficacy of a Combination of Flumazenil and Gabapentin in the Treatment of Alcohol Dependence”, Anton RF, Myrick H., et al., Journal of Clinical Psychopharmacology, Volume 29, Number 4, August 2009, pp. 334-342. The study was conducted at the Medical University of South Carolina, and among the researchers’ findings were that key results demonstrated a statistically significant difference in use for subjects who exhibited pre-treatment withdrawal symptoms. The results are the first to be published in a peer-reviewed scientific journal from a double-blind, placebo-controlled study conducted to assess the impact of the PROMETA Treatment Program on alcohol dependence.
“We are pleased that results from the double-blind, placebo-controlled studies are beginning to publish in academic journals,” said Hythiam’s Senior Vice President of Scientific Affairs, Dr. Gary Ingenito. “Peer-review publication brings additional validation to the PROMETA Treatment Program, and results from the alcohol studies are providing greater clarity for clinicians as to when use of the PROMETA Treatment Program in alcohol dependent patients may be beneficial. We look forward to several publications of results from other completed double-blind studies in peer-reviewed journals, and expect those results to help create a more complete picture regarding the impact of the PROMETA Treatment Program on substance dependence.”
http://www.hythiam.com
Study links heavy drinking to increased heart disease risk in young women